Ozone Therapy for Oral Palatal Ulcer in a Leukaemic Patient
Giacomo Oldoini1, Giulia Ricci Frabattista2, Maria Saragoni2, Saverio Cosola1, Enrica Giammarinaro1, Anna Maria Genovesi1, Simone Marconcini1
1Tuscan Stomatologic Institute, Versilia General Hospital, Lido di Camaiore, Italy
2Private clinician, Liguria, Italy
Doi: 10.12890/2020_001406 - European Journal of Case Reports in Internal Medicine - © EFIM 2019
Received: 27/11/2019
Accepted: 30/11/2019
Published: 14/01/2020

How to cite this article: Oldoini G, Ricci Frabattista G, Saragoni M, Cosola S, Giammarinaro E, Genovesi AM, Marconcini S. Ozone theraphy for oral palatal ulcer in a leukaemic patient. EJCRIM 2020;7 doi:10.12890/2020_001406.

Conflicts of Interests: The authors declare there are no competing interests.
This article is licensed under a Commons Attribution Non-Commercial 4.0 License


Chemotherapy usually causes complications affecting several tissues such as oral mucosa. In this case report, a soft palate oral ulcer caused by chemotherapy was treated by ozone gas. This kind of treatment is known for its antimicrobial, regenerative and analgesic proprieties. The results show a complete resolution of the lesion within 2 weeks of treatment. Ozone therapy demonstrates greater effectiveness with respect to this kind of oral lesion compared to traditional therapy. Considering this evidence, ozone therapy should be considered as a useful tool for the adjuvant therapy of oral complications in oncologic patients.



Ozone therapy, leukaemia, adjuvant therapy, oral ulcer, oral fungal infections, ozone, dentistry


The treatment for acute lymphocytic leukaemia (ALL) in adults is usually long-term chemotherapy. Intensive chemo regimens are undertaken to obtain better clinical responses, but may also lead to complications and side effects. In these patients, if the immune system is damaged, opportunistic infections can occur and, sometimes, complications can be serious enough to be life-threatening. Today, thanks to the multidisciplinary approach regarding supportive care (nursing care, nutrition, antibiotics, growth factors and so on) for oncologic patients, these life-threatening episodes are far less common than in the past[1].
Side effects of chemotherapy affect rapidly proliferating cells, such as in the bone marrow, intestinal mucosa, oral mucosa, hair follicles and gonads. In particular, in oral mucosa, basal cells are lysed, replacement and turnover slow down resulting in mucosal ulcerations, or other oral damage such as aphthous lesions, mucositis and oral candidiasis caused by immunodepression[2].
Ozone is a gas known for its antibacterial, antiviral and antifungal properties and it is widely used in medicine and dentistry[3]. Medical ozone can improve the microcirculation and it has anti-inflammatory, analgesic and immune-modulating properties. All of these characteristics qualify medical ozone as a valid candidate within clinical dentistry, especially for the treatment of soft tissues.
From a pharmacological point of view, ozone therapy follows the principle of hormesis: it has high efficacy with lower concentrations, but at a greater dosage, it can be ineffective, or even toxic. At low dosage, this powerful oxidizing agent stimulates endogenous antioxidant activity and the production of interleukins and leukotrienes, causing a reduction in inflammation and pain.
In this article, an ulcerative lesion located in the soft palate has been treated by ozone as an adjuvant therapy in a leukaemic patient undergoing an intensive chemo regimen[4].


The patient was a 69-year-old male who was sent to the Tuscan Stomatologic Institute because of an oral lesion diagnosed as major aphthous ulcers that had not healed over 25 days. Anamnestic data were collected. The patient suffered from lymphoblastic Ph+ leukaemia (ALL) and was on his second chemotherapy cycle with monoclonal antibodies, namely, blinatumomab. The oral lesion was classified as an ulcerative lesion of the oral palatal tissue, probably due to the side effects of these therapies on the oral cavity. The ulcerative lesion had already appeared 7 days after chemotherapy started, causing, at the beginning, just a light sting and then, after 25 days, it had developed into an extended ulcer. During these 25 days, antibiotic, antimycotic, analgesic and opioid medications had been prescribed to treat the lesion by haematologists and otorhinolaryngologists (FANS, opioids, amoxicillin and clavulanic acid, morphine, oxycodone, econazole, vitamins and oral gel specific for aphthosis).
The lesion did not heal; instead, it became chronic so the haematologist of the patient decided to suspend chemotherapeutical treatment until the lesion disappeared completely. This meant the lesion needed to be resolved as soon as possible.
The patient reported a constant and strong pain, similar to a jellyfish burn, which made it impossible for him to eat, drink and swallow, risking other systemic problems due to malnutrition. Consequently, the patient suffered from xerostomia caused by dehydration and drugs.
On first inspection at the Tuscan Stomatologic Institute (T0), that is, 25 days after the oral lesion had started, the ulcer (Fig. 1) located in the soft palate was more than 2 cm in diameter and several millimeters in depth. Above the lesion and on the back of the tongue there was a Candida suprainfection, which did not respond to antimycotic medication. The ulcer was treated using an ozone generator device (OZONE DTA, Sweden & Martina, Padua, Italy), which develops ozone from environmental oxygen. When ozone therapy started, all other treatments were interrupted except for antimycotic treatment of opportunistic infections. The patient could also still take analgesics (opioids or ketoprofen) when needed, and a sodium hyaluronic spray with amino acids (Aminogam, Polifarma Benessere, Italy) several times during the day.
The first ozone session consisted of 5 applications of 2 minutes each, gradually increasing the power from 5 to 9. The insert utilized was the n #5 for mucosal use. The top of the probe in contact with the tissue released energy along the treated area. The ozone concentration was between 10 and 100 µg/ml. The patient felt pain during the first applications and the lesion was wetted with saline solution to reduce discomfort. At the end of the first session, the patient had already reported a reduction in pain, and he was able again to swallow and drink water. The patient returned after 2 days (T1). The diameter and the depth of the lesion had decreased, the colour was more natural (a pinkish colour) and the oedema was reduced (Fig. 2). After this second session, the production of saliva increased, the Candida infection was reduced and the patient stopped opioid intake, continuing with just ketoprofen once a day.

Figure 1 (click to enlarge)

Figure 2 (click to enlarge)

Figure 1. Initial photo, T0
Figure 2. T1, 2 days after the first applications

The treatment continued with ozone applications (10 minutes each) every 2 days, using the mucosal and angled insert, alternatively, in order to also reach the deepest zone of the soft palate (Fig. 3 and Fig. 4). Constant improvements were clinically appreciable and were noticed also by the patient. After 15 days, the lesion was remarkably reduced so doctors decided to restart the antitumoural therapy (Fig. 5). After 22 days (Fig. 6), the ozone treatment was ended after a last application of ozone gas with the same machine and ozonated water (2 cycles of 1.5 minutes using the Aquolab® Professional). After 1 month, the patient returned for monitoring of lesion healing (Fig. 7).

Figure 3 (click to enlarge)

Figure 4(click to enlarge)

Figure 5 (click to enlarge)

Figure 3. Four days after the first applications
Figure 4. Eight days after the first applications
Figure 5. Fifteen days after the first applications

Figure 6 (click to enlarge)

Figure 7 (click to enlarge)

Figure 6. Last applications of ozone, 22 days after the first applications
Figure 7. No treatment, follow-up 31 days after the first ozone applications


The most frequent oral complications of antitumoural therapy are mucositis, ulcerative lesions, oral infections, pain and salivary gland dysfunction[5]. In order to treat these kinds of lesions, oncologic patients are often monitored by other specialists to control complications before they become chronic. In some cases, the pharmacologic therapy may not be enough, and the patient may also need adjuvant therapy to facilitate the healing process, preventing correlated complications such as dehydration and malnutrition[6]. Ozone stimulates the release of interleukins and leukotrienes, reducing inflammation and promoting healing of the damaged tissues[7]. Ozone treatment causes nitric oxide release, which is a vasodilator. Nitric oxide improves the red cells tissue blood perfusion and stimulates aerobic processes such as glycolysis and the Krebs cycle[8,9]. Based on this evidence, ozone therapy was also shown to play an important role in reducing oral lichen planus symptoms[10].
Chlorhexidine was considered the gold standard for treating several infections and inflammatory diseases in the oral cavity but it has certain side effects, especially with prolonged treatment. Kaur and co-workers (2019) reported better results, even if not statistically significant, with ozonated water irrigation than with 0.2% chlorhexidine gluconate irrigation in the management of periodontal disease in 20 patients[11]. Other studies have reported encouraging effects of ozone irrigation combined with or as an alternative to chlorhexidine, because it may shift the oral microbiota to health[12,13].
According to a review by Kaimala et al. (2018), the oral microbiota could also help patients by acting as an immunotherapeutic agent modulating the immune system[14]. Furthermore, ozone has a high level of biocompatibility with epithelial cells, mucosal cells and fibroblast cells, along with its effects on other biological actions such as biosynthetic, haemostatic, bioenergetic, analgesic and antihypoxic processes, and these properties of ozone are refined upon contact with water (as in the oral cavity)[15,16].
This biological rationale and these clinical results encourage clinicians to collaborate for a multidisciplinary medicine where oncologic patients are also supervised by a dentist to monitor or prevent the complications of chemotherapy.


In this clinical case, an ulcerative lesion located in the soft palate of a patient undergoing chemotherapy was treated by ozone therapy. The initial pain and extensions of the lesion forced clinicians to interrupt the chemotherapy and start treating the lesions with antibiotic, antimycotic, analgesic and opioid medications, without evident improvements. Only after the use of ozone therapy as an adjuvant therapy was tissue damage fully recovered, and the patient reported no pain; he could stop antibiotic, antimycotic, analgesic and opioid treatment and start chemotherapy again.
The results of this clinical case are highly encouraging, although further research is needed to standardize the ozone therapy clinical procedure and its indications with large sample sizes and prospective studies.

  1. Peterson DE, Srivastava R, Lalla RV. Oral mucosal injury in oncology patients: perspectives on maturation of a field. Oral Dis 2015;21(2):133–141.
  2. Pai A, Prasad S, Dyasanoor S. Acute leukemias: a dentist's perspective. Minerva Stomatol 2012;61(5):233–238.
  3. Huth KC, Jakob FM, Saugel B, Cappello C, Paschos E, Hollweck R, et al. Effect of ozone on oral cells compared with established antimicrobials. Eur J Oral Sci 2006;114(5):435–440.
  4. Iebba V, Totino V, Gagliardi A, Santangelo F, Cacciotti F, Trancassini M, et al. Eubiosis and dysbiosis: the two sides of the microbiota. New Microbiol 2016;39(1):1–12.
  5. Bocci VA. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res 2006;37(4):425–435.
  6. Saini R. Ozone therapy in dentistry: a strategic review. J Nat Sci Biol Med 2011;2(2):151–153.
  7. Roy D, Wong PK, Engelbrecht RS, Chian ES. Mechanism of enteroviral inactivation by ozone. Appl Environ Microbiol 1981;41(3):718–723.
  8. Seydanur Dengizek E, Serkan D, Abubekir E, Aysun Bay K, Onder O, Arife C. Evaluating clinical and laboratory effects of ozone in non-surgical periodontal treatment: a randomized controlled trial. J Appl Oral Sci 2019;27:e20180108.
  9. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 2007;18(5):1071–1075.
  10. Kazancioglu HO, Erisen M. Comparison of low-level laser therapy versus ozone therapy in the treatment of oral lichen planus. Ann Dermatol 2015;27(5):485–491.
  11. Kaur A, Bhavikatti SK, Das SS, Khanna S, Jain M, Kaur A. Efficacy of ozonised water and 0.2% chlorhexidine gluconate in the management of chronic periodontitis when used as an irrigant in conjugation with phase I therapy. J Contemp Dent Pract 2019;20(3):318–323.
  12. Dodwad V, Gupta S, Kumar K, Sethi M, Masamatti S. Changing paradigm in pocket therapy - ozone vs conventional irrigation. Int J of Public Health Dent 2011:2(2):7–12.
  13. Cosola S, Giammarinaro E, Genovesi AM, Pisante R, Poli G, Covani U, et al. A short-term study of the effects of ozone irrigation in an orthodontic population with fixed appliances. Eur J Paediatr Dent 2019;20(1):15–18.
  14. Kaimala S, Al-Sbiei A, Cabral-Marques O, Fernandez-Cabezudo MJ, Al-Ramadi BK. Attenuated bacteria as immunotherapeutic tools for cancer treatment. Front Oncol 2018;8:136.
  15. Akdeniz SS, Beyler E, Korkmaz Y, Yurtcu E, Ates U, Araz K, et al. The effects of ozone application on genotoxic damage and wound healing in bisphosphonate-applied human gingival fibroblast cells. Clin Oral Investig 2018;22(2):867–873.
  16. Nogales CG, Ferrari PH, Kantorovich EO, Lage-Marques JL. Ozone therapy in medicine and dentistry. J Contemp Dent Pract 2008;9(4):75–84.